(062) Testosterone Therapy Improves Mortality after Solid Organ Transplant

Abstract Introduction Low testosterone has been suggested as a contributor to mortality and rejection after solid organ transplant. Whether therapy specifically improves these outcomes is unknown. Objective To determine whether treatment of low with associated improved or transplant using TriNetX, large deidentified, multi-institutional database. Methods We compiled all clinical data from the TriNetX research network, globally federated health network (with waiver Western IRB) that provides de-identified information 58 heath care organizations, over 80 million patients located within United States. selected male (aged ≥ 18) history lung, kidney, liver, heart, pancreas categorized into two groups, based on prescription for therapy. For patients, we collected including demographics, comorbidities, laboratory findings, medication use. Our interest were 1-year, 3-year, all-time mortality, well allograft rejection. evaluated differences in baseline characteristics between level (Normal T, T), chi-square Fisher’s exact test categorical (presented frequencies percentages), independent t-test continuous data. address potential confounders could bias our results, used propensity score weighted regression (inverse probability weighting), matched age, race/ethnicity, comorbid conditions, multiple status, immunosuppressant Multivariable logistic was model outcome rejection, predictors level, therapy, their interaction, while cox mortality. Results A total 1,762 men identified transplants. 262 (14.9 %) met criteria had Baseline similar groups (Table 1). After matching existing patient characteristics, showed The risk reduced at 1 year (HR 0.33), 3 years (HR0.57) time 0.61) among treated No effect seen regards (data not shown). Conclusions Testosterone may improve serum following Further studies are required when what derive most benefit therapies, particularly result does appear be driven by Disclosure